Tags

Type your tag names separated by a space and hit enter

Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome.
Hum Reprod. 2008 Oct; 23(10):2352-8.HR

Abstract

BACKGROUND

Polycystic ovary syndrome (PCOS) is associated with insulin resistance and features in common with the metabolic syndrome (MetS)--factors shown to predict cardiovascular risk and type 2 diabetes. We investigated the prevalence and characteristics of the MetS in PCOS by three definitions-World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP-III) and International Diabetes Federation (IDF)--and compared that with the background population.

METHODS

Cross-sectional study of 168 women with PCOS and 883 age-matched controls from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study.

RESULTS

Prevalence of the MetS in PCOS subjects was 33% by WHO, 37% by NCEP-ATP-III and 40% by IDF criteria, compared with 10% by NCEP-ATP-III and 13% by IDF in controls (P < 0.001). MetS by WHO criteria was not calculated in the AusDiab population. Age was an independent predictor of MetS in PCOS and controls. The prevalence of MetS was significantly higher among those with PCOS (P = 0.027) in obese women (BMI > 30 kg/m(2)), and higher but not significantly so in overweight (BMI 25-30 kg/m(2)) women (P = 0.052). Dehydroepiandrosterone sulphate was associated with a lower risk of the MetS--Odds ratio 0.86 (95% confidence interval, 0.77-0.97, P = 0.011).

CONCLUSIONS

An approximate 4-fold increase in the prevalence of the MetS in women with PCOS compared with the general population, consistent with the proposed major role of insulin and obesity in the syndrome, implies greater risk of cardiometabolic disease in women with PCOS. However, this estimate is likely to vary according to PCOS definition, ethnicity and different aetiological pathways to PCOS.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Cussons AJ
Keogh Institute for Medical Research, Nedlands, WA, Australia.
Watts GF
No affiliation info available
Burke V
No affiliation info available
Shaw JE
No affiliation info available
Zimmet PZ
No affiliation info available
Stuckey BG
No affiliation info available

MeSH

AdultAge FactorsCross-Sectional StudiesFemaleHumansMetabolic SyndromeMiddle AgedPolycystic Ovary SyndromePrevalenceRegression Analysis

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18635531

Citation

Cussons, Andrea J., et al. "Cardiometabolic Risk in Polycystic Ovary Syndrome: a Comparison of Different Approaches to Defining the Metabolic Syndrome." Human Reproduction (Oxford, England), vol. 23, no. 10, 2008, pp. 2352-8.
Cussons AJ, Watts GF, Burke V, et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod. 2008;23(10):2352-8.
Cussons, A. J., Watts, G. F., Burke, V., Shaw, J. E., Zimmet, P. Z., & Stuckey, B. G. (2008). Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Human Reproduction (Oxford, England), 23(10), 2352-8. https://doi.org/10.1093/humrep/den263
Cussons AJ, et al. Cardiometabolic Risk in Polycystic Ovary Syndrome: a Comparison of Different Approaches to Defining the Metabolic Syndrome. Hum Reprod. 2008;23(10):2352-8. PubMed PMID: 18635531.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. AU - Cussons,Andrea J, AU - Watts,Gerald F, AU - Burke,Valerie, AU - Shaw,Jonathan E, AU - Zimmet,Paul Z, AU - Stuckey,Bronwyn G A, Y1 - 2008/07/16/ PY - 2008/7/19/pubmed PY - 2009/2/26/medline PY - 2008/7/19/entrez SP - 2352 EP - 8 JF - Human reproduction (Oxford, England) JO - Hum Reprod VL - 23 IS - 10 N2 - BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and features in common with the metabolic syndrome (MetS)--factors shown to predict cardiovascular risk and type 2 diabetes. We investigated the prevalence and characteristics of the MetS in PCOS by three definitions-World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP-III) and International Diabetes Federation (IDF)--and compared that with the background population. METHODS: Cross-sectional study of 168 women with PCOS and 883 age-matched controls from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. RESULTS: Prevalence of the MetS in PCOS subjects was 33% by WHO, 37% by NCEP-ATP-III and 40% by IDF criteria, compared with 10% by NCEP-ATP-III and 13% by IDF in controls (P < 0.001). MetS by WHO criteria was not calculated in the AusDiab population. Age was an independent predictor of MetS in PCOS and controls. The prevalence of MetS was significantly higher among those with PCOS (P = 0.027) in obese women (BMI > 30 kg/m(2)), and higher but not significantly so in overweight (BMI 25-30 kg/m(2)) women (P = 0.052). Dehydroepiandrosterone sulphate was associated with a lower risk of the MetS--Odds ratio 0.86 (95% confidence interval, 0.77-0.97, P = 0.011). CONCLUSIONS: An approximate 4-fold increase in the prevalence of the MetS in women with PCOS compared with the general population, consistent with the proposed major role of insulin and obesity in the syndrome, implies greater risk of cardiometabolic disease in women with PCOS. However, this estimate is likely to vary according to PCOS definition, ethnicity and different aetiological pathways to PCOS. SN - 1460-2350 UR - https://www.unboundmedicine.com/medline/citation/18635531/Cardiometabolic_risk_in_polycystic_ovary_syndrome:_a_comparison_of_different_approaches_to_defining_the_metabolic_syndrome_ L2 - https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/den263 DB - PRIME DP - Unbound Medicine ER -